CN117045757A - 一种调理新陈代谢阻碍、降低尿酸浓度的组合物及其制备方法 - Google Patents
一种调理新陈代谢阻碍、降低尿酸浓度的组合物及其制备方法 Download PDFInfo
- Publication number
- CN117045757A CN117045757A CN202311174430.0A CN202311174430A CN117045757A CN 117045757 A CN117045757 A CN 117045757A CN 202311174430 A CN202311174430 A CN 202311174430A CN 117045757 A CN117045757 A CN 117045757A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- uric acid
- acid concentration
- reducing uric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 45
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 41
- 229940116269 uric acid Drugs 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 230000004060 metabolic process Effects 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 230000001105 regulatory effect Effects 0.000 title claims description 18
- 235000003222 Helianthus annuus Nutrition 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 25
- 240000003915 Lophatherum gracile Species 0.000 claims abstract description 23
- 239000001387 apium graveolens Substances 0.000 claims abstract description 23
- 244000246386 Mentha pulegium Species 0.000 claims abstract description 22
- 235000016257 Mentha pulegium Nutrition 0.000 claims abstract description 22
- 235000004357 Mentha x piperita Nutrition 0.000 claims abstract description 22
- 235000001050 hortel pimenta Nutrition 0.000 claims abstract description 22
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 21
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 21
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 21
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 21
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 21
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 21
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 21
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 21
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 21
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 21
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 21
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 21
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 17
- 244000197580 Poria cocos Species 0.000 claims abstract description 16
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 16
- 244000292697 Polygonum aviculare Species 0.000 claims abstract description 13
- 235000006386 Polygonum aviculare Nutrition 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 6
- 244000020551 Helianthus annuus Species 0.000 claims abstract 6
- 240000007171 Imperata cylindrica Species 0.000 claims abstract 6
- 201000005569 Gout Diseases 0.000 claims description 13
- 230000005764 inhibitory process Effects 0.000 claims description 12
- 244000185386 Thladiantha grosvenorii Species 0.000 claims description 9
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 claims description 9
- 240000007087 Apium graveolens Species 0.000 claims description 6
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 claims description 6
- 235000010591 Appio Nutrition 0.000 claims description 6
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 6
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 6
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 6
- 235000011477 liquorice Nutrition 0.000 claims description 6
- 240000000691 Houttuynia cordata Species 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 4
- 235000013717 Houttuynia Nutrition 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 240000005979 Hordeum vulgare Species 0.000 claims description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 2
- 244000228293 Persicaria perfoliata Species 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 18
- 230000003750 conditioning effect Effects 0.000 abstract description 15
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 201000010099 disease Diseases 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 8
- 239000000463 material Substances 0.000 abstract description 8
- 201000001431 Hyperuricemia Diseases 0.000 abstract description 6
- 230000006378 damage Effects 0.000 abstract description 4
- 210000001835 viscera Anatomy 0.000 abstract description 4
- 230000000593 degrading effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 27
- 208000002193 Pain Diseases 0.000 description 21
- 230000036407 pain Effects 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 241000208818 Helianthus Species 0.000 description 19
- 241001598107 Imperata Species 0.000 description 17
- 241001092040 Crataegus Species 0.000 description 15
- 230000002503 metabolic effect Effects 0.000 description 12
- 230000001737 promoting effect Effects 0.000 description 11
- 239000013078 crystal Substances 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 6
- HJXMNVQARNZTEE-UHFFFAOYSA-N Butylphthalide Chemical compound C1=CC=C2C(CCCC)OC(=O)C2=C1 HJXMNVQARNZTEE-UHFFFAOYSA-N 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 235000006679 Mentha X verticillata Nutrition 0.000 description 4
- 235000002899 Mentha suaveolens Nutrition 0.000 description 4
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 206010061428 decreased appetite Diseases 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000000582 semen Anatomy 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 description 3
- 206010038743 Restlessness Diseases 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000005337 ground glass Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 201000009240 nasopharyngitis Diseases 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 2
- 235000013719 Houttuynia cordata Nutrition 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 229950005197 butylphthalide Drugs 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000012488 skeletal system development Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 241000745390 Lophatherum Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 206010046337 Urate nephropathy Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 229940089837 amygdalin Drugs 0.000 description 1
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002579 anti-swelling effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000021259 spicy food Nutrition 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000023409 throat pain Diseases 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种调理新陈代谢阻碍、降低尿酸浓度的组合物及其制备方法,具体涉及医药领域。所述组合物包括茯苓、陈皮、山楂、薏米、芹菜籽、淡竹叶、白茅根、薄荷、桃仁、葵花盘、罗汉果和杠板归。本发明通过采用中医古方并加以改进,选取的原料即可食用,亦可入药;找到患病原因,从而调理患者身体内在新陈代谢阻碍,疏通各脏器於堵,降解嘌呤成分,达到根除高尿酸指标,因药食同源材料,所以对人体无任何伤害。
Description
技术领域
本发明涉及医药领域,具体涉及一种调理新陈代谢阻碍、降低尿酸浓度的组合物及其制备方法。
背景技术
痛风是由尿酸盐晶体沉积于关节、肌肉、韧带处所引起的一种关节炎症性疾病。其中单核/巨噬细胞系统在痛风启动、进展及缓解中均发挥了关键作用,其病理特点是尿酸盐晶体募集的外周巨噬细胞浸润关节腔并极化为M1型巨噬细胞参与炎症的启动,M1型巨噬细胞释放IL-1β、IL-6和TNF-α等致炎性因子和蛋白酶,炎性因子和蛋白酶进一步趋化白细胞,使更多吞噬尿酸钠晶体的白细胞破裂释放出蛋白酶和炎性成分,形成恶性循环而导致炎症呈瀑布式级联放大,患处可出现不同程度的滑膜增生、软骨侵蚀及破坏,引起剧烈的疼痛;在炎症后期则极化为M2型巨噬细胞,其分泌Arg、TGF-β1、IL-4、IL-10细胞因子发挥了抗炎作用,促进痛风的缓解;其中长期持续性的高尿酸血症会引起尿酸盐结晶在肾小管中沉积,进而出现肾脏靶器官损害,可进展为痛风性肾病。因此,治疗痛风药物疗效的好坏,很大程度体现在精准抗炎、无副降酸、靶向护肾的综合作用上。
现有治疗痛风手段基本上为:服用镇痛药和手术(切除结晶体),无法从根本上解决病痛,且对患者有伤害,镇痛药服用时间长了对患者脏器造成伤害(即毒副作用),而手术切除结晶体并没有从根本上消除患者痛因,都只是暂时性减轻患者痛苦,患者得病原理没找到。
发明内容
为此,本发明提供一种调理新陈代谢阻碍、降低尿酸浓度的组合物及其制备方法,以解决现有治疗痛风不彻底的问题。
本发明依据中国传统的古方经典《金匮要略》组方,并顺应时代发展需要,在原组方基础上增、减四、五味同源材料,用最贴近现代人体身体结构状况,重新组合成一个新配方,目的是消除高血尿酸,清理嘌呤成份,让患者身心轻松。
本发明完全采用中医古方并加以改进(依时代发展需要,增减部分草药成分,宗旨不变:药食同源,选取原材料完全符合2018年国家87种药食同源(修订版)汇总目录中食材,即可食用,亦可入药;找到患病原因,从而调理患者身体内在新陈代谢阻碍,疏通各脏器於堵,降解嘌呤成分,达到根除高尿酸指标,因药食同源材料,所以对人体无任何伤害。
为了实现上述目的,本发明提供如下技术方案:
根据本发明第一方面提供的一种调理新陈代谢阻碍、降低尿酸浓度的组合物,所述组合物包括茯苓、陈皮、山楂、薏米、芹菜籽、淡竹叶、白茅根、薄荷、桃仁、葵花盘、罗汉果和杠板归。
此12味食药均有可替代品,如甘草可替代陈皮、薏米、茯苓,杠板归鱼腥草3-5g替代杠板归,只是剂量要少于杠板归,因鱼腥草性寒,量大易伤肠胃。
进一步的,所述组合物包括茯苓2-5份,陈皮2-5份,山楂2-5份,薏米2-5份,芹菜籽2-5份,淡竹叶1-4份,白茅根1-4份,薄荷1-4份,桃仁1-4份,葵花盘3-5份,罗汉果1-4份,杠板归5-10份。
进一步的,所述组合物包括茯苓3.5g,陈皮3.5g,山楂3.5g,薏米3.5g,芹菜籽3.5g,淡竹叶2.5g,白茅根2.5g,薄荷2.5g,桃仁2.5g,葵花盘3-5g,罗汉果2.5g,杠板归5-10g。
根据本发明第二方面提供的一种调理新陈代谢阻碍、降低尿酸浓度的组合物,所述组合物包括山楂3-5份,甘草6-15份,芹菜籽2-5份,淡竹叶1-4份,白茅根1-4份,薄荷1-4份,桃仁1-4份,葵花盘3-5份,罗汉果1-4份,杠板归5-10份。
根据本发明第三方面提供的一种调理新陈代谢阻碍、降低尿酸浓度的组合物,所述组合物包括茯苓2-5份,陈皮2-5份,山楂2-5份,薏米2-5份,芹菜籽2-5份,淡竹叶1-4份,白茅根1-4份,薄荷1-4份,桃仁1-4份,葵花盘3-5份,罗汉果1-4份,鱼腥草3-5份。
根据本发明第四方面提供的一种调理新陈代谢阻碍、降低尿酸浓度的组合物的制备方法,其特征在于,包括按比例称取原料混合后,采用高精密粉碎机碾成粉末200目-2000目粉末,灌装成条状即得。
根据本发明第五方面提供的一种调理新陈代谢阻碍、降低尿酸浓度的组合物在制备治疗痛风产品中的应用。
进一步的,所述产品为药食同源组合物、中药组合物或保健品。
茯苓是一种寄生于松树根的菌类植物,形状似甘薯,外皮黑褐色,里面白色或粉红色。茯苓功效广泛,不分四季,将其与各种药物配伍,不管寒、湿、温、风诸症,都能发挥其独特功效。具有利水渗湿、健脾和胃、养心安神之功效。
陈皮,健脾开胃、燥湿化痰。因其含有特殊芳香,能改善食欲、促进消化液分泌,增强肠道功能,缓解脘腹胀满、食欲不振、食少吐泻症状。泡水喝可起到燥湿化痰作用,可去除体内湿气,促进痰液排出,对于咳嗽痰多有一定缓解作用。现代临床常用于辅治疗支气管炎、肺炎等疾病。
山楂,消食健胃、行气散瘀、化浊降脂。因其含有丰富果酸以及有机酸,能刺激消化液分泌,改善脾胃功能、缓解泻痢腹痛、胃脘胀满、食欲不振、肉食积滞症状。山楂归脾经、胃经、肝经,还可行气散瘀,对产后瘀阻、瘀血经闭、胸痹心痛等病症有一定调理效果。此外,山楂具有化浊降脂作用,适合高脂血症患者食用。
薏米,利水消肿、健脾止泻。薏米,味甘淡、性微寒,入脾、胃、肺、大肠经。有利水消肿、健脾止泻功效。可用于治疗水肿、泄泻。薏米不但有滋补作用,还能降血压、解热。除痹、清热、排脓,功同茯苓,尤对脾虚湿盛者效果不错,同时用于风湿痹痛、筋脉挛急,因其能渗湿,又能疏筋脉,缓挛急,所以用于这一类疾病效果佳。
芹菜籽,预防高血压、壮骨、祛风除湿。芹菜籽即为芹菜种子,显种形,颜色多为棕褐色或深棕色。芹菜籽加工或粉剂可直接食用,能为人体补充多种有益的营养成分,具有预防高血压、壮骨:祛风除湿之功效。芹菜籽中含有纯天然降压成分,长期食用可辅助降压、使血压稳定。芹菜籽中还含微量元素钙和磷,是人体骨骼发育的重要成分,可促进骨骼发育,增加骨骼密度,预防骨质疏松、降低骨关节疾病的发病率。芹菜籽还具有一定的药用价值,能祛风除湿及疏通经络,对关节炎、风湿性关节炎、关节疼痛有缓解作用。另外,芹菜籽中含有的碱性成分能加快人体内尿酸代谢,患痛风的几率会明显下降。现代药理研究发现,芹菜籽中提取的丁基苯酞(Butylphthalidde.NBP),可以有效治疗急性缺血性脑卒中(石药集团发明专利药:丁苯酞软胶囊)。
淡竹叶,清热除烦、利尿。淡竹叶上能清心火而除烦,可用于治疗热病烦渴、口舌生疮、小便赤涩、疼痛等症。淡竹叶下能利小便而渗湿,所以可治湿热黄疸等症。淡竹叶性味甘,淡、寒,与温补辅助的药物和辛辣食物同用,可降低药效。现代药理研究可知,本品有退热、利尿、抗肿痛、抑菌、升高血糖等多种药理作用。
薄荷,疏散风热:解毒透疹、清利头目。薄荷是一种有特殊价值的芳香植物,中国常用药之一,既有药用价值,又有食用价值。在日常生活中,可用薄荷叶泡茶喝,有保健作用。薄荷具有疏散风热、解毒透疹:清利头目功效。疏散风热,主要用于风热感冒症,临床上表现为发烧、怕冷、嗓子疼、头痛、咳嗽、咳吐黄痰或咳痰不爽,大便偏干等感冒症状。解毒透疹,对麻疹疹出不畅,用薄荷可使麻疹透发出来,缩短病程。清利头目、通鼻窍。用于外感风热或外感风寒入里热化引起的咽喉疼痛、头痛等症状,以及二感冒或过敏引起鼻塞、流鼻涕。疏肝理气,薄荷具有疏肝解郁、理气功效。对于肝气不舒引起的协肋瘀肿、心情不畅、失眠多梦、郁郁寡欢等症状可起到缓解作用。
白茅根,凉血止血、清热生津、利尿通淋。白茅根为禾本植物,其干燥根茎呈长圆柱形,表面黄白色或淡黄色,微有光泽,体轻,质略脆,断面皮部白色,气微,味微甘。凉血止血,白茅根性寒味甘,能凉血止血,治疗血热妄行之吐血、咳血、尿血等出血症。白茅根性寒,味甘,归脾经、胃经丶膀胱经,《本草纲目》:止吐衄血诸症,伤寒哕逆,肺热喘急,水肿黄胆、解酒毒。白茅根含丰富的钾盐,可清热利尿、除湿退黄、小便不利功效较好。
桃仁,润肠通便、活血化瘀、止咳平喘,桃仁质润,有润肠通便功效,可缓解肠火筹引起的大便干结、排便困难、腹痛等病症以及跌打损伤引起的痰血肿痛。现代药理研究发现,桃仁中含有的杏仁苷具有止咳平喘功效,有助于缓解咳嗽、气喘等症状。
葵花盘,清热平肝、止血止痛、降压。葵花盘性寒、归肝经,对于肝阳上亢导致的头晕耳鸣、舌红少津、头重脚轻等症状有一定治疗效果。葵花盘还具有止血止痛作用,适用于治疗崩漏、痛经、脘腹痛、尿血、子宫出血等病症。此外,现代药理研究表明,葵花盘能够扩张周围血管、降低血压、减慢心率、保护心血管,适合高血压患者。葵花盘粉中的有效成分对降低血尿酸有显著作用。痛风属风湿免疫病范畴,是一种代谢紊乱症,根本原因是由于嘌呤代谢阻碍导致体内嘌呤含量高引起的免疫疾病。其发病与否与血尿酸升高有密切关系,通过降低血尿酸浓度而减少痛风发病率。除此之外,多饮水、减重、减少摄入高嘌呤食物,增加碱性食物摄入量,也是一种降低痛风发病的好办法。
罗汉果,清热生津、解表除烦、润肠通便。罗汉果味甘、性凉;归肺、大肠经。具有清肺热作用,常用于治疗咽喉肿痛、声音嘶哑。此外,罗汉果还可用于治疗肠热便秘、食欲不振、消化不良等;还可用于治疗毛玻璃肺结节。毛玻璃结节是指肺部的一种毛玻璃影,它密度比较高,边界比较清楚。现代研究显示,罗汉果有降低血清谷丙转氨酶活力作用,能较显著提高动物外固血酸性醋酸奈酷酶阳性淋巴细胞的百分率,提示可增强机体的细胞免疫功能。本组方无任何添加剂、无催化剂等额外物质,所有成分均来自天然食材(大地上生长的植物)。
本发明具有如下优点:
本发明整体调理患者新陈代谢紊乱问题,降低血尿酸浓度,新陈代谢受阻问题解决好了,身体各结构得到疏通,患者身体自然健康了,并且服用剂量无需严格控制,根据自己疼痛程度可增可减,当食品服用。
本发明依据中国传统的古方经典《金匮要略》组方,并顺应时代发展需要,在原组方基础上增、减四、五味同源材料,用最贴近现代人体身体结构状况,重新组合成一个新配方,目的是消除高血尿酸,清理嘌呤成份,让患者身心轻松。
本发明完全采用中医古方并加以改进(依时代发展需要,增减部分草药成分,宗旨不变:药食同源,选取原材料完全符合2018年国家87种药食同源(修订版)汇总目录中食材,即可食用,亦可入药;找到患病原因,从而调理患者身体内在新陈代谢阻碍,疏通各脏器於堵,降解嘌呤成分,达到根除高尿酸指标,因药食同源材料,所以对人体无任何伤害。
本发明的制备方法简单:只需添置一台高精度粉碎机,尽量达到纳米级细微颗粒,这样能直接穿透细胞膜被吸收,使尿酸快速排出体外。
具体实施方式
以下由特定的具体实施例说明本发明的实施方式,熟悉此技术的人士可由本说明书所揭露的内容轻易地了解本发明的其他优点及功效,显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1
本实施例提供一种调理新陈代谢阻碍、降低尿酸浓度的组合物:
茯苓3.5g,陈皮3.5g,山楂3.5g,薏米3.5g,芹菜籽3.5g,淡竹叶2.5g,白茅根2.5g,薄荷2.5g,桃仁2.5g,葵花盘4g,罗汉果2.5g,杠板归8g。
实施例2
本实施例提供一种调理新陈代谢阻碍、降低尿酸浓度的组合物:
茯苓2g,陈皮2g,山楂2g,薏米2g,芹菜籽2g,淡竹叶1g,白茅根1g,薄荷1g,桃仁1g,葵花盘3g,罗汉果1g,杠板归5g。
实施例3
本实施例提供一种调理新陈代谢阻碍、降低尿酸浓度的组合物:
茯苓5g,陈皮5g,山楂5g,薏米5g,芹菜籽5g,淡竹叶4g,白茅根4g,薄荷4g,桃仁4g,葵花盘5g,罗汉果4g,杠板归10g。
实施例4
本实施例提供一种调理新陈代谢阻碍、降低尿酸浓度的组合物:
山楂3.5g,甘草10.5g,芹菜籽3.5g,淡竹叶2.5g,白茅根2.5g,薄荷2.5g,桃仁2.5g,葵花盘4g,罗汉果2.5g,杠板归8g。
实施例5
本实施例提供一种调理新陈代谢阻碍、降低尿酸浓度的组合物:
甘草6g,山楂2g,芹菜籽2g,淡竹叶1g,白茅根1g,薄荷1g,桃仁1g,葵花盘3g,罗汉果1g,杠板归5g。
实施例6
本实施例提供一种调理新陈代谢阻碍、降低尿酸浓度的组合物:
山楂5g,甘草15g,芹菜籽5g,淡竹叶4g,白茅根4g,薄荷4g,桃仁4g,葵花盘5g,罗汉果4g,杠板归10g。
实施例7
本实施例提供一种调理新陈代谢阻碍、降低尿酸浓度的组合物:
茯苓3.5g,陈皮3.5g,山楂3.5g,薏米3.5g,芹菜籽3.5g,淡竹叶2.5g,白茅根2.5g,薄荷2.5g,桃仁2.5g,葵花盘4g,罗汉果2.5g,鱼腥草4g。
实施例8
本实施例提供一种调理新陈代谢阻碍、降低尿酸浓度的组合物:
茯苓2g,陈皮2g,山楂2g,薏米2g,芹菜籽2g,淡竹叶1g,白茅根1g,薄荷1g,桃仁1g,葵花盘3g,罗汉果1g,鱼腥草3g。
实施例9
本实施例提供一种调理新陈代谢阻碍、降低尿酸浓度的组合物:
茯苓5g,陈皮5g,山楂5g,薏米5g,芹菜籽5g,淡竹叶4g,白茅根4g,薄荷4g,桃仁4g,葵花盘5g,罗汉果4g,鱼腥草5g。
实施例10
本实施例提供一种调理新陈代谢阻碍、降低尿酸浓度的组合物的制备方法:
称取原料混合,采用高精密粉碎机碾成粉末200目-2000目粉末,灌装成条状即得。
实验例1
通过对120例痛风患者服用本组合方跟踪监测(服用本组方剂前的三甲医院所做血尿酸检测(生化24项,主要血尿酸指标),第一组为中、轻症者,即尿酸指标不到350的80例;第二组为重症患者350—700及以上的40例;第一组服用本组方剂连续服用7天量,每天上午、下午各一条(每条含量4g),第二组,加量×2条,上、下午各2条;无餐前、餐后要求。服用本品同时,要求患者多饮温白开水,更好帮助代谢,清理肠胃。
第一组80人,第三天关节疼痛感消失,匀速步行亦无痛感:此类人群72例,均回复无疼痛感,并在同一家三甲医院做一次生化24项检测,尿酸指标恢复正常值;有效率达90%。
第二组40人,其中血尿酸指标500及以上至700多的26例,加量每天上、下午各二条,连续服用14天,26例患者亲述第三、四天疼痛感减轻,但第七、八天疼痛感加强,因尿酸指标超过500者大多都有关节部位形成结晶,而结晶在溶解过程中尿酸会升高,所以患者陈述结晶部位的关节更痛,继续服用完毕,第十四天即无痛感,仅快速步行踝关节会有少许痛感;有效率达100%;剩余14人中,有12人陈述,第四天或第五天疼痛感减轻,7天疼痛感剋完全消失。
虽然,上文中已经用一般性说明及具体实施例对本发明作了详尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
Claims (8)
1.一种调理新陈代谢阻碍、降低尿酸浓度的组合物,其特征在于,所述组合物包括茯苓、陈皮、山楂、薏米、芹菜籽、淡竹叶、白茅根、薄荷、桃仁、葵花盘、罗汉果和杠板归。
2.根据权利要求1所述的一种调理新陈代谢阻碍、降低尿酸浓度的组合物,其特征在于,所述组合物包括茯苓2-5份,陈皮2-5份,山楂2-5份,薏米2-5份,芹菜籽2-5份,淡竹叶1-4份,白茅根1-4份,薄荷1-4份,桃仁1-4份,葵花盘3-5份,罗汉果1-4份,杠板归5-10份。
3.根据权利要求1所述的一种调理新陈代谢阻碍、降低尿酸浓度的组合物,其特征在于,所述组合物包括茯苓3.5g,陈皮3.5g,山楂3.5g,薏米3.5g,芹菜籽3.5g,淡竹叶2.5g,白茅根2.5g,薄荷2.5g,桃仁2.5g,葵花盘3-5g,罗汉果2.5g,杠板归5-10g。
4.一种调理新陈代谢阻碍、降低尿酸浓度的组合物,其特征在于,所述组合物包括山楂3-5份,甘草6-15份,芹菜籽2-5份,淡竹叶1-4份,白茅根1-4份,薄荷1-4份,桃仁1-4份,葵花盘3-5份,罗汉果1-4份,杠板归5-10份。
5.一种调理新陈代谢阻碍、降低尿酸浓度的组合物,其特征在于,所述组合物包括茯苓2-5份,陈皮2-5份,山楂2-5份,薏米2-5份,芹菜籽2-5份,淡竹叶1-4份,白茅根1-4份,薄荷1-4份,桃仁1-4份,葵花盘3-5份,罗汉果1-4份,鱼腥草3-5份。
6.一种调理新陈代谢阻碍、降低尿酸浓度的组合物的制备方法,其特征在于,包括按比例称取原料混合后,采用高精密粉碎机碾成粉末200目-2000目粉末,灌装成条状即得。
7.一种调理新陈代谢阻碍、降低尿酸浓度的组合物在制备治疗痛风产品中的应用。
8.根据权利要求7所述的应用,其特征在于,所述产品为药食同源组合物、中药组合物或保健品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311174430.0A CN117045757A (zh) | 2023-09-12 | 2023-09-12 | 一种调理新陈代谢阻碍、降低尿酸浓度的组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311174430.0A CN117045757A (zh) | 2023-09-12 | 2023-09-12 | 一种调理新陈代谢阻碍、降低尿酸浓度的组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117045757A true CN117045757A (zh) | 2023-11-14 |
Family
ID=88667674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311174430.0A Pending CN117045757A (zh) | 2023-09-12 | 2023-09-12 | 一种调理新陈代谢阻碍、降低尿酸浓度的组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117045757A (zh) |
-
2023
- 2023-09-12 CN CN202311174430.0A patent/CN117045757A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111588042A (zh) | 一种辅助降低尿酸和控制痛风的膳食营养调理食品 | |
CN108404019A (zh) | 复方菊苣根调节嘌呤代谢紊乱的固体制品及其制备方法 | |
CN110915970A (zh) | 一种具有降低尿酸盐沉积的中药压片糖果及其制备方法 | |
CN101530565A (zh) | 一种治疗糖尿病的中药制剂及其制备方法 | |
CN117045757A (zh) | 一种调理新陈代谢阻碍、降低尿酸浓度的组合物及其制备方法 | |
CN112294925A (zh) | 一种用于治疗痛风、胃病、便秘的药物及其制备方法 | |
KR101391647B1 (ko) | 항비만 조성물 | |
CN110478416A (zh) | 治疗风湿性类风湿性关节炎的组合物及其制备方法和应用 | |
CN104606538A (zh) | 一种用于预防和治疗糖尿病的中药保健品 | |
CN115317457B (zh) | 一种牛用健胃促反刍中药片及其制备方法 | |
CN113499402B (zh) | 一种治疗肠易激综合征的中药组合物及制备方法 | |
CN104971157A (zh) | 一种治疗脚气的外搽粉及制法 | |
CN106668704A (zh) | 回族中药参木胃癌散颗粒及其制备方法 | |
CN103520408A (zh) | 一种健脑补肾保健品及其制备方法 | |
CN114515299A (zh) | 一种治疗高尿酸血症的提取物及其制备方法和应用 | |
KR101391648B1 (ko) | 항비만 조성물 | |
CN113288979A (zh) | 一种降尿酸和缓解痛风的组合物 | |
CN106692413A (zh) | 一种治疗小儿疳积病的中药制剂 | |
CN106668422A (zh) | 回族中药食管遏癌颗粒及其制备方法 | |
CN104815269A (zh) | 一种治疗小儿食积的中药组合物及制备方法 | |
CN106668752A (zh) | 回族中药参木胃癌散片及其制备方法 | |
CN106668421A (zh) | 回族中药舌草食管抗癌颗粒及其制备方法 | |
CN106039051A (zh) | 一种水貂幼崽专用营养膏及其制备方法 | |
CN106668408A (zh) | 回族中药食管遏癌丸及其制备方法 | |
CN106668406A (zh) | 回族中药三子胃癌康口服液及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |